Navigation Links
Genencor Launches Accellerase(R) 1500, Next Step Toward Scale-Up of Cellulosic Ethanol
Date:2/24/2009

PALO ALTO, Calif., Feb. 24 /PRNewswire/ -- Today, Genencor, a division of Danisco A/S, launched Accellerase(R) 1500, the next generation of its cellulosic ethanol enzyme product. Genencor introduced the product at the Renewable Fuels Association (RFA) 2009 National Ethanol Conference in San Antonio, TX.

Accellerase(R) 1500 is another significant step toward commercialization of biofuels and other biochemicals made from cellulosic feedstocks, such as agricultural residues and bioenergy crops. It also reinforces Genencor's position as a global leader in 2nd generation ethanol innovation.

"We're on course to fast-track commercialization of cellulosic ethanol," says Philippe Lavielle, Senior Vice President, Business Development, Genencor. "Accellerase was a breakthrough in the industry. Now, by launching this improved enzyme product, we reach another important technical milestone toward commercial-scale production of transportation fuel and other biochemicals from renewable, non-food feedstocks."

Accellerase(R) 1500 will lower one of the major cost hurdles to producing ethanol or biochemicals from cellulosic feedstocks, such as corn stover, sugarcane bagasse, wood chips, wheat straw, and switchgrass. In addition, Accellerase(R) 1500 has a significantly improved formulation and higher activity resulting in higher ethanol yields and robust operation in a wider variety of processes. The product is based on Genencor's patented gene expression technology and the division's 25-year history of biofuels research.

Accellerase(R) is critical to the hydrolysis step of converting biomass to ethanol or other biochemicals. In this step, plant material is broken down into sugars for fermentation to ethanol.

Genencor supplies Accellerase(R) as part of its dual-strategy to drive forward the cellulosic ethanol industry, which includes its dedicated enzyme business, and its joint venture DuPont Danisco Cellulosic Ethanol LLC (DDCE), which develops and provides integrated technology packages for biomass ethanol production.

Genencor, a division of Danisco A/S, is a world leader in industrial biotechnology and a pioneer in enzyme innovation. Genencor improves process and product performance for a spectrum of industries, from biofuels and laundry detergents to animal nutrition and food. As part of a large global organization, Genencor has a manufacturing and distribution network that spans more than 40 countries. In collaboration with customers, technology leaders and other stakeholders, Genencor supplies competitive, biobased solutions. These innovations create value throughout the supply chain, from raw material to finished product.


'/>"/>
SOURCE Genencor
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. DuPont and Genencor Create World-Leading Cellulosic Ethanol Company
2. Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
3. Genencor Appoints New Executive Vice President - Technical Enzymes
4. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
5. EyeScience Launches Comprehensive Online Resource Devoted to Age-Related Macular Degeneration Education and Prevention
6. Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement
7. CUREXO Technology Corporation Launches Its ROBODOC(R) Surgical System at Upcoming Orthopaedic Conference in Las Vegas
8. BioSpace.com Launches a New Season of Industry Career Fairs
9. Millipore Launches an Interactive Biological Pathway Tool Using GeneGos Manually Curated Pathway Maps
10. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
11. Cephalons New Product Launches Pace Record 2008 Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and SAN FRANCISCO , Feb. ... regenerative medicine company, and Beyond Type 1, a not-for-profit ... 1 diabetes, today announced a grant from Beyond Type ... cure for type 1 and other insulin-requiring diabetes.  ... been developing innovative stem cell-derived cell replacement therapies with ...
(Date:2/22/2017)... ... February 22, 2017 , ... Kernel , ... Research Systems, LLC (KRS) clinical development program. KRS is a neurotechnology spin-out ... research and clinical applications. The terms of the transaction were not disclosed. ...
(Date:2/22/2017)... 2017 Scientists propose in Nature ... in Gaucher and maybe other lysosomal storage diseases as ... than current therapies. An international research team ... which also included investigators from the University of L├╝beck ... Feb. 22. The study was conducted in mouse models ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , ... from around the world, is pleased to announce the 2nd annual Precision Medicine ... This premier, online-only conference focused on the development and advancements in precision medicine. ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):